ESMO Preceptorship on Gastric Cancer Prague 2016

Oncology Meeting Resources

10 Jun - 11 Jun, Prague, Czech Republic

ESMO Preceptorships Gastric Cancer square

The ESMO Preceptorship on Gastric Cancer Prague 2016 was designed for learning about the fundamentals of epidemiology, etiology, pathogenesis, molecular events and ethnic patterns as contributing factors to heterogeneity in gastric cancer; understanding the essentials in the diagnosis and multidisciplinary treatment of gastric cancer; learning about advances in the treatment and novel targets in gastric cancer.

Presentations of the ESMO Preceptorship on Gastric Cancer Prague 2016 are available to ESMO members according to the presenters' agreement to release them. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful links

Presenter Presentation title Session title
A. Cervantes, SP Case discussion based on ESMO recommendations/guidelines Practical case discussion
J.Y. Douillard, FR Objectives of the meeting Opening and welcome
A. Cervantes, SP Epidemiology (including GE junction tumours) and clinical presentation Epidemiology, pathology and endoscopy of gastric cancer
F. Carneiro, PT Pathology and carcinogenesis Epidemiology, pathology and endoscopy of gastric cancer
F. Caillol, FR Endoscopy in gastric cancer: new imaging techniques, new treatment modalities (EMR, ESD) Epidemiology, pathology and endoscopy of gastric cancer
W. Aillum, UK Surgery for gastric and GE junction cancer, primary, palliative - where and when? Surgical, adjuvant and neoadjuvant treatment of gastric cancer
K. Haustermans, BE Neo- and adjuvant treatment for gastric cancer and GE junction cancer: The role of radiotherapy Surgical, adjuvant and neoadjuvant treatment of gastric cancer
I. Chau, UK Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Surgical, adjuvant and neoadjuvant treatment of gastric cancer
F. Carneiro, PT Molecular events and classification in gastric cancer and hereditary gastric cancer Clinical discussions
I. Chau, UK Chemotherapy for metastatic disease Advanced disease
J.Y. Douillard, FR Biological targeted agents (including HER2, EGFR, angiogenesis) Advanced disease
A. Cervantes, SP New targets (including cMET, FGF, mTOR, PDL . . .) Advanced disease
R. Romanidou, GR Biomarker driven treatment of gastric cancer- changing prognosis? Case discussions and questions
C. D. Ciochir, RO A 76-year-old man with gastric cancer: evolution and treatment Case discussions and questions
L. Cantini, IT Long survival in patient with advanced remnant gastric cancer Case discussions and questions